Analysis of Circulating Biomarkers in the Randomized, Double-Blind, Placebo-Controlled PORTOLA Phase 2a Study Evaluating Zetomipzomib, a Selective Immunoproteasome Inhibitor, in Patients with Autoimmune Hepatitis